P2, N=41, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting

Our findings support the existence of a subset of extranodal follicular lymphomas lacking an IGH::BCL2 rearrangement and highlight alternative pathways of lymphomagenesis with implications for classification and diagnosis. The identification of biallelic CREBBP mutations and a FOXO1 mutation provides molecular insight into extranodal FL biology, suggesting an overlap with nodal FL while supporting alternative oncogenic pathways in extranodal disease.

P1, N=75, Recruiting, Hoffmann-La Roche

P=N/A, N=30, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P1/2, N=6, Not yet recruiting, F. Hoffmann-La Roche AG

P2/3, N=15, Not yet recruiting, F. Hoffmann-La Roche AG

P3, N=250, Recruiting, University Hospital, Montpellier | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Jun 2031 | Initiation date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2030 --> Jun 2031

The Zanubrutinib, Lenalidomide, and Rituximab regimen appears to have promising efficacy and acceptable safety in treating relapsed/refractory PCNSL, particularly for patients with the MCD subtype.

Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.

P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P2, N=43, Not yet recruiting, AIDS Malignancy Consortium

Overall, most biologic therapies appear broadly reassuring with respect to overall malignancy, although non-melanoma skin cancer remains the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept. Rituximab retains a favorable profile in patients with prior lymphoproliferative disease, whereas IL-6 and IL-17/23 pathway inhibitors appear largely neutral or reassuring in currently available datasets...We further examine tumor-type-specific patterns, major modifiers of risk, and practical risk-stratified management strategies. The central clinical message is that malignancy safety in IMIA should be interpreted through an individualized framework that balances inflammatory control against oncologic vulnerability rather than through uniform class-based avoidance.